AZD7687 is primarily used in research settings as a potent and selective inhibitor of diacylglycerol lipase (DAGL), an enzyme involved in the biosynthesis of endocannabinoids. Its application is significant in studying the role of endocannabinoid signaling in various physiological and pathological processes, including pain, inflammation, and neurological disorders. Researchers utilize AZD7687 to explore potential therapeutic strategies targeting the endocannabinoid system, particularly in conditions where modulating DAGL activity could provide clinical benefits. Additionally, it serves as a tool compound in preclinical studies to understand the complex mechanisms underlying endocannabinoid-mediated pathways.